Evidence map›Paper›PMID 36202484›Full record

ReviewRadiologic clinics of North America2022

Diagnosis and Treatment of Lung Cancer in the Setting of Interstitial Lung Disease.

Dane A Fisher, Mark C Murphy, Sydney B Montesi, Lida P Hariri, Robert W Hallowell, Florence K Keane, Michael Lanuti, Meghan J Mooradian, Florian J Fintelmann

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Radiologic clinics of North America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. TheJournal of clinical medicine · 2024
    Review
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Dane A FisherDepartment of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Mark C MurphyDepartment of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Sydney B MontesiDivision of Pulmonology and Critical Care Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Lida P HaririDepartment of Pathology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Robert W HallowellDivision of Pulmonology and Critical Care Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Florence K KeaneDepartment of Radiation Oncology, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Michael LanutiDepartment of Surgery, Division of Thoracic Surgery, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA.
Meghan J MooradianMassachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA.
Florian J FintelmannDepartment of Radiology, Division of Thoracic Imaging and Intervention, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: fintelmann@mgh.harvard.edu.
Massachusetts General Hospital · US

Funding

Vascular Leak and Outcomes in IPFK23HL150331 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MONTESI, SYDNEY · 2020 to 2024
$887k
NHLBI NIH HHS K23 HL150331
6 · The paper itself

Abstract

Interstitial lung disease (ILD) including idiopathic pulmonary fibrosis increases the risk of developing lung cancer. Diagnosing and staging lung cancer in patients with ILD is challenging and requires careful interpretation of computed tomography (CT) and fluorodeoxyglucose PET/CT to distinguish nodules from areas of fibrosis. Minimally invasive tissue sampling is preferred but may be technically challenging given tumor location, coexistent fibrosis, and pneumothorax risk. Current treatment options include surgery, radiation therapy, percutaneous thermal ablation, and systemic therapy; however, ILD increases the risks associated with each treatment option, especially acute ILD exacerbation.

Indexed as

Idiopathic Pulmonary FibrosisLung Diseases, InterstitialLung NeoplasmsFibrosisHumansLungPositron Emission Tomography Computed TomographyIdiopathic pulmonary fibrosisInterstitial lung diseaseLung cancerPercutaneous thermal ablationRadiation therapy

Identifiers

PMID36202484
PMCPMC9969995
OpenAlexW4294477903

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.